Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Diabetica Ltd.

This article was originally published in Start Up

Executive Summary

In contrast to a host of companies pursuing GLP-1 pathway in diabetes, Diabetica is pioneering GIP research. Because there is currently no marketed antagonist to make insulin work better in the body, as Diabetica believes its GIP agonist will, the company hopes that, at the end of the day, it won't be competing with other compounds at all.

Related Content

Best of Blog: Start-Up March 2008
The Double-edged Sword of Diabetes Drug Development


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts